Company Product Description Indication Status
Masimo Corp., of Irvine, Calif. Masimo Sedline Brain Function Monitoring Module that plugs into the Root patient monitoring platform Offers multiple views of brain monitoring information Published study in Anesthesia Research and Practice to investigate the depth of sedation of patients receiving propofol for outpatient colonoscopy; researchers monitored 119 adult patients undergoing outpatient colonoscopies using Masimo Sedline Brain Function Monitoring, including its Patient State Index (PSi), which provides values that range from 0-100, with higher values indicating lesser degrees of sedation (with values from 50-25 indicative of general anesthesia, and below 25 for burst suppression); found that 118 of the 119 patients attained PSi values of <50, consistent with general anesthesia, and that these patients spent a significantly greater percentage of the procedure with PSi values <50 (53.1% of the time) vs. >50 (42% of the time) (p = 0.001); of the 118 patients, 27.7% attained PSi values of <25, consistent with burst suppression; the researchers found the mean total dose of propofol was significantly correlated with PSi during periods of PSi values <25 (R = 0.406, p = 0.021)
Natera Inc., of San Carlos, Calif. Signatera Personalized circulating tumor DNA (ctDNA) test For treatment monitoring and molecular residual disease assessment in patients previously diagnosed with cancer Study published in Nature Cancer validates Signatera's ability to to evaluate tumor response to immunotherapy in 25 different types of solid cancer; the prospective phase II INSPIRE study followed patients with advanced solid tumors being treated with pembrolizumab; Signatera technology detected ctDNA before treatment in 98% of cases (92/94); an increase of ctDNA after just 6 weeks of treatment, together with increasing tumor volume on imaging, was identified in 42% of patients (30/73) and predicted treatment non-response with 100% accuracy; ctDNA clearance at any time point during treatment was achieved by 16% of patients (12/73) and was associated with 100% overall survival with a median of 25.4 months of followup beyond first clearance

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments